Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Non-Current Assets of $19.8 million for Q1 2026, down 76.08% YoY from $82.6 million in Q1 2025, and down 5.4% sequentially from $20.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Non-Current Assets across 17 years of filings, most recently posting $19.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 76.08% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $135.5 million (down 63.49% YoY), while the FY2025 annual figure was $20.9 million, down 76.77% from the prior year.
- Non-Current Assets eased to $19.8 million in Q1 2026, from $20.9 million in the prior quarter.
- Over the last five years, Non-Current Assets for AMRN reached as high as $254.1 million in Q2 2022 and fell as low as $19.8 million in Q1 2026.
- The 5-year median for Non-Current Assets is $102.1 million (2024), against an average of $120.1 million.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 418.74% — and 2025, when it tumbled 76.77%.
- A 5-year view of Non-Current Assets shows it stood at $197.1 million in 2022, then slumped by 45.86% to $106.7 million in 2023, then decreased by 15.7% to $90.0 million in 2024, then plunged by 76.77% to $20.9 million in 2025, then decreased by 5.4% to $19.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $19.8 million, $20.9 million, and $31.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 19.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.76 Mn |
| Dec 31, 2025 | 20.89 Mn |
| Sep 30, 2025 | 31.51 Mn |
| Jun 30, 2025 | 63.33 Mn |
| Mar 31, 2025 | 82.64 Mn |
| Dec 31, 2024 | 89.95 Mn |
| Sep 30, 2024 | 100.40 Mn |
| Jun 30, 2024 | 98.10 Mn |
| Mar 31, 2024 | 102.11 Mn |
| Dec 31, 2023 | 106.70 Mn |
| Sep 30, 2023 | 121.52 Mn |
| Jun 30, 2023 | 153.52 Mn |
| Mar 31, 2023 | 176.39 Mn |
| Dec 31, 2022 | 197.08 Mn |
| Sep 30, 2022 | 221.78 Mn |
| Jun 30, 2022 | 254.14 Mn |
| Mar 31, 2022 | 201.09 Mn |
| Dec 31, 2021 | 189.34 Mn |
| Sep 30, 2021 | 72.77 Mn |
| Jun 30, 2021 | 48.99 Mn |